Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group
Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Joseph Treat(Fox Chase Cancer Center), Gary Richardson(Cabrini Hospital), Reinhard von Roemeling(Daiichi Sankyo (United States)), Anthony G. Arcenas(Royal Adelaide Hospital), Vera Hirsh(Taipei Veterans General Hospital), Bengt Bergman(Sahlgrenska University Hospital), Ian Olver(The University of Adelaide), Joseph Ayoub(Ontario Institute for Cancer Research), U. Gatzemeier(Ontario Institute for Cancer Research), Lars Ove Elisson(Royal Adelaide Hospital), Jean Viallet(Agir Pour les Maladies Chroniques), Michael Boyer(Chris O’Brien Lifehouse), David J. Dunlop(Charles University), Peter Clark(National Cancer Centre Japan), Robert Vescio(Royal Adelaide Hospital), A Rey(Royal Adelaide Hospital), Denis Talbot(Royal Adelaide Hospital), Thomas W. Butler(Royal Adelaide Hospital)
Cited by 286
Related Papers
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
|JNCI Journal of the National Cancer Institute|1993|15.9k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k